ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "C-reactive protein (CRP)"

  • Abstract Number: 1214 • ACR Convergence 2020

    Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies

    John Tesser1, Grace Wright2, Vibeke Strand3, Jeffrey Kaine4, Karina Maslova5, Gregory St John6, Kerri Ford5, Amy Praestgaard5 and Ernest Choy7, 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2Association of Women in Rheumatology, New York, NY, 3Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 4Independent Rheumatology Consultant, Sapphire, NC, 5Sanofi, Cambridge, MA, 6Regeneron Pharmaceuticals Inc, Tarrytown, NY, 7CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Evaluation of response to RA therapy at 12 weeks after initiation is recommended in treatment guidelines. CRP response after 12 weeks of therapy may…
  • Abstract Number: 1232 • ACR Convergence 2020

    Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)

    Andrea Rubbert Roth1, Daniel Furst*2, Stefano Fiore3, Amy Praestgaard4, Vivian Bykerk5, Clifton Bingham III6 and Christina Charles-Schoeman7, 1Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, 2Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, 3Sanofi, Bridgewater, NJ, 4Sanofi, Cambridge, MA, 5Hospital for Special Surgery, New York, NY, 6Johns Hopkins University, Baltimore, MD, 7University of California, Los Angeles, Los Angeles, CA

    Background/Purpose: Anemia is a common comorbidity in patients (pts) with RA, and changes in hemoglobin (Hb) levels are associated with changes in inflammatory disease activity. Since…
  • Abstract Number: 1358 • ACR Convergence 2020

    Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status

    Atul Deodhar1, Lianne Gensler2, Stephen Hall3, Philip Robinson4, Bengt Hoepken5, Lars Bauer5, Thomas Kumke5 and Walter Maksymowych6, 1Oregon Health & Science University, Portland, OR, 2University of California San Francisco, San Francisco, CA, 3Cabrini Medical Centre, Monash University and Emeritus Research, Malvern, Victoria, Australia, 4University of Queensland, Herston, Queensland, Australia, 5UCB Pharma, Monheim am Rhein, Germany, 6University of Alberta, Edmonton, AB, Canada

    Background/Purpose: This post-hoc analysis from the phase 3 C-axSpAnd study aimed to evaluate whether the response to certolizumab pegol (CZP) in non-radiographic axial spondyloarthritis (nr-axSpA)…
  • Abstract Number: 1366 • ACR Convergence 2020

    Secukinumab Improved Signs and Symptoms in Patients with Non-radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study Stratified by Baseline Objective Signs of Inflammation

    Juergen Braun1, Ricardo Blanco2, Helena Marzo-Ortega3, Lianne Gensler4, Filip Van den Bosch5, Hideto Kameda6, Denis Poddubnyy7, Marleen van de Sande8, Anna Wiksten9, Brian Porter10, Santiago Moreno9, Abhijit Shete9, Hanno Richards9, Sibylle Haemmerle9 and Atul Deodhar11, 1Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany, 2Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 3The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, 4University of California San Francisco, San Francisco, CA, 5Ghent University Hospital, Ghent, Belgium, 6Toho University, Tokyo, Japan, 7Charité – Universitätsmedizin Berlin, Berlin, Germany, 8Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, 9Novartis Pharma AG, Basel, Switzerland, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ, 11Oregon Health & Science University, Portland, OR

    Background/Purpose: Active non-radiographic axial spondyloarthritis (nr-axSpA) is often determined on the basis of objective signs of inflammation (elevated C-reactive protein [CRP] and/or evidence of sacroiliitis…
  • Abstract Number: 1891 • ACR Convergence 2020

    Impact of Utilising Smart Phone Application in Ankylosing Spondylitis: SMART- as Study

    Ashit Syngle1, Nidhi Garg2 and Kanchan Chauhan1, 1Healing Touch City Clinic, Chandigarh, Chandigarh, India, 2Chitkara University, Rajpura, Punjab, India

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton and characterized by inflammatory back pain, leading to decreased mobility,…
  • Abstract Number: 1904 • ACR Convergence 2020

    Clinical Features of Patients with Active Ankylosing Spondylitis Who Did Not Respond to Adalimumab but Responded to Ixekizumab: A Post-hoc Analysis

    Xenofon Baraliakos1, Rebecca Bolce2, David Sandoval2, Soyi Liu-Leage3, Vladimir Geneus3, David Adams3, Atul Deodhar4, Jessica Walsh5 and Joachim Sieper6, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, 2Eli Lilly and Company, Indianapolis, 3Eli Lilly and Company, Indianapolis, IN, 4Oregon Health & Science University, Portland, OR, 5University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, 6Charité Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Biologic therapy is recommended in patients with active ankylosing spondylitis (AS) despite adequate trial of NSAIDs. Biologic treatment in AS are currently limited to…
  • Abstract Number: 2006 • ACR Convergence 2020

    Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

    Markus Rehberg1, Clemens Giegerich1, Amy Praestgaard2, Hubert van Hoogstraten3, Melitza Iglesias-Rodriguez2, Jeffrey R Curtis4, Jacques-Eric Gottenberg5, Andreas Schwarting6, Santos Castañeda7, Andrea Rubbert Roth8 and Ernest Choy9, 1Sanofi, Frankfurt, Germany, 2Sanofi, Cambridge, MA, 3Sanofi, Bridgewater, NJ, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Strasbourg University Hospital, Strasbourg, France, 6Johannes Gutenberg University, Mainz, Germany, 7Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 8Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, 9CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Despite the existence of guidelines for DMARD treatment of RA, a more individualized approach to treatment is needed to maximize efficacy while minimizing risk…
  • Abstract Number: 0034 • ACR Convergence 2020

    Gene Expression Signatures in C-Reactive Protein High and Low Rheumatoid Arthritis

    Adam Cornish1, Kristin Wipfler1 and Kaleb Michaud2, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Transcriptome profiling has expanded our ability to identify biomarkers and therapeutic targets and better understand disease progression in a wide variety of conditions. Serum…
  • Abstract Number: 0097 • ACR Convergence 2020

    Does Testing for SAA Is More Beneficial Than CRP for the Follow-up of Patients with FMF?

    Mert Oztas1, Serdal Ugurlu1, Oguzhan Selvi2, Bilgesu Ergezen1 and Huri Ozdogan1, 1Istanbul University-Cerrahpasa, Istanbul, Turkey, 2Okmeydani Research and Training Hospital, Istanbul, Turkey

    Background/Purpose: In order to follow subclinical inflammation and adjust the therapy for an optimal disease control, clinicians seek for readily accessible, affordable and reproducible markers.…
  • Abstract Number: 0404 • ACR Convergence 2020

    Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management

    Nadia Ahmad1, Ayna Verdiyeva2, Raashid Luqmani2 and Shirish Dubey2, 1Oxford University Hospitals NHS Foundation Trust, Reading, United Kingdom, 2Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

    Background/Purpose: Aortitis was previously regarded as a rare form of large vessel vasculitis (LVV), but is now increasingly being recognised. It may occur in the…
  • Abstract Number: 0626 • ACR Convergence 2020

    Early Rise in CRP Is Associated with Progression to Respiratory Failure and Intubation in COVID-19 Patients

    Alisa Mueller1, Tomoyoshi Tamura2, Julia Jezmir3, Erin Penn1, Gregory Keras4, Anthony Massaro5 and Edy Kim5, 1Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 2Brigham and Women's Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, 3Brigham and Women’s Hospital, Department of Medicine, Boston, MA, 4Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 5Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA

    Background/Purpose: During the course of hospitalization, it is often unclear which COVID-19 patients will progress from non-critical to critical illness. Timely identification of these patients…
  • Abstract Number: 0827 • ACR Convergence 2020

    Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis

    Thomas Huizinga1, Ernest Choy2, Amy Praestgaard3, Hubert van Hoogstraten4, Patrick R LaFontaine3, Patricia Guyot5, Daniel Aletaha6, Ulf Müller-Ladner7, Yoshiya Tanaka8, Jeffrey R Curtis9 and Roy Fleischmann10, 1Leiden University Medical Center, Leiden, Netherlands, 2CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 3Sanofi, Cambridge, MA, 4Sanofi, Bridgewater, NJ, 5Sanofi, Chilly-Mazarin, France, 6Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, 7Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, 8The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 9Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 10Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…
  • Abstract Number: 0828 • ACR Convergence 2020

    Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study

    Stanley B Cohen1, Yi-Hsing Chen2, Naonobu Sugiyama3, Jose L Rivas4, Annette Diehl5, Tatjana Lukic6, Jerome Paulissen7, Haiyun Fan5, Tomohiro Hirose3 and Edward C Keystone8, 1Metroplex Clinical Research Center, Dallas, TX, 2Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), 3Pfizer Japan Inc, Tokyo, Japan, 4Pfizer SLU, Madrid, Spain, 5Pfizer Inc, Collegeville, PA, 6Pfizer Inc, New York, NY, 7Syneos Health, Morrisville, NC, 8Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: ORAL Shift (NCT02831855) was a 48-week Phase 3b/4 study, which demonstrated sustained efficacy/safety of tofacitinib modified release 11 mg once daily (QD) following MTX…
  • Abstract Number: 340 • 2019 ACR/ARP Annual Meeting

    Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels

    Naomi Schlesinger1, Kyle Jablonski 2, Peter Harb 3, Caitlin Henry 3, Emily Schwarz 3, Ifeoma Okafor 3, Wael Jarjour 4 and Nicholas Young 5, 1Rutgers Health- RWJ Medical School, New Brunswick, NJ, 2The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, 3Ohio State College of Medicine, Columbus, 4Ohio State College of Medicine, Columbus, OH, 5The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH

    Background/Purpose: Regular exercise programs were previously thought to be inappropriate in patients with rheumatic diseases because of the potential to exacerbate inflammation. However, while recent paradigm-shifting…
  • Abstract Number: 1398 • 2019 ACR/ARP Annual Meeting

    Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)

    Christine Xu1, Patrick Nolain 2, Qiang Lu 3, Anne Paccaly 4, Melitza Iglesias-Rodriguez 5, Gregory St John 6, Chad Nivens 4, Rafael Maldonado 7, Tomonori Ishii 8, Ernest Choy 9 and Vanaja Kanamaluru 3, 1Sanofi, Bridgewater, NJ, 2Sanofi-Aventis, Montpellier, France, 3Sanofi, Bridgewater, 4Regeneron Pharmaceuticals, Inc., Tarrytown, 5Sanofi Genzyme, Cambridge, MA, 6Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 7Pompeu Fabra University, Barcelona, Spain, 8Tohoku University Hospital, Sendai, Japan, 9Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose: The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15–22-fold higher than that of tocilizumab. This…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.